{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T14:12:57Z","timestamp":1764079977083},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,4]]},"DOI":"10.7759\/cureus.49898","type":"journal-article","created":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T12:23:54Z","timestamp":1701692634000},"source":"Crossref","is-referenced-by-count":1,"title":["5-Fluorouracil Neurotoxicity in a Patient With Normal Dihydropyrimidine Dehydrogenase Activity"],"prefix":"10.7759","author":[{"given":"Ulaganathan","family":"Natarajan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Afoma","family":"Onyechi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Ohemeng-Dapaah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.658636","article-title":"5-Fluorouracil: a narrative review on the role of regulatory mechanisms in driving resistance to this chemotherapeutic agent","volume":"11","author":"Ghafouri-Fard S","year":"2021","unstructured":"Ghafouri-Fard S, Abak A, Anamag FT, et al.. 5-Fluorouracil: a narrative review on the role of regulatory mechanisms in driving resistance to this chemotherapeutic agent. Front Oncol. 2021, 11:658636. 10.3389\/fonc.2021.658636","journal-title":"Front Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2002.17.1.73","article-title":"A case of neurotoxicity following 5-fluorouracil-based chemotherapy","volume":"17","author":"Ki SS","year":"2002","unstructured":"Ki SS, Jeong JM, Kim SH, et al.. A case of neurotoxicity following 5-fluorouracil-based chemotherapy. Korean J Intern Med. 2002, 17:73-7. 10.3904\/kjim.2002.17.1.73","journal-title":"Korean J Intern Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1097\/01.COT.0000450350.19112.9c","article-title":"5-FU overdose may be countered by new antidote pill","volume":"36","author":"Susman E","year":"2014","unstructured":"Susman E. 5-FU overdose may be countered by new antidote pill. Oncol Times. 2014, 36:p42. 10.1097\/01.COT.0000450350.19112.9c","journal-title":"Oncol Times"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12790","article-title":"Beating the odds: efficacy and toxicity of dihydropyrimidine dehydrogenase-driven adaptive dosing of 5-FU in patients with digestive cancer","volume":"81","author":"Launay M","year":"2016","unstructured":"Launay M, Dahan L, Duval M, et al.. Beating the odds: efficacy and toxicity of dihydropyrimidine dehydrogenase-driven adaptive dosing of 5-FU in patients with digestive cancer. Br J Clin Pharmacol. 2016, 81:124-30. 10.1111\/bcp.12790","journal-title":"Br J Clin Pharmacol"},{"key":"ref5","article-title":"Fluorouracil Therapy and DPYD Genotype","author":"Dean L","year":"2012","unstructured":"Dean L, Kane M. Fluorouracil Therapy and DPYD Genotype. Pratt VM, Scott SA, Pirmohamed M, Esquivel B, Kattman BL, Malheiro AJ (ed): Medical Genetics Summaries, Bethesda (MD); 2012."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1080\/07357900500524702","article-title":"Screening for dihydropyrimidine dehydrogenase deficiency: to do or not to do, that's the question","volume":"24","author":"van Kuilenburg AB","year":"2006","unstructured":"van Kuilenburg AB. Screening for dihydropyrimidine dehydrogenase deficiency: to do or not to do, that's the question. Cancer Invest. 2006, 24:215-7. 10.1080\/07357900500524702","journal-title":"Cancer Invest"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1177\/19418744211068913","article-title":"5-fluorouracil neurotoxicity in the absence of dihydropyrimidine dehydrogenase deficiency case report","volume":"12","author":"Jules R","year":"2022","unstructured":"Jules R, Thaper A, Foster R, et al.. 5-fluorouracil neurotoxicity in the absence of dihydropyrimidine dehydrogenase deficiency case report. Neurohospitalist. 2022, 12:366-70. 10.1177\/19418744211068913","journal-title":"Neurohospitalist"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.14.10.961","article-title":"Acute cerebellar syndrome secondary to 5-fluorouracil therapy","volume":"14","author":"RI JL","year":"1964","unstructured":"RI JL, BR WJ. Acute cerebellar syndrome secondary to 5-fluorouracil therapy. Neurology. 1964, 14:961-7. 10.1212\/wnl.14.10.961","journal-title":"Neurology"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyi214","article-title":"Intermediate dose 5-fluorouracil-induced encephalopathy","volume":"36","author":"Kim YA","year":"2006","unstructured":"Kim YA, Chung HC, Choi HJ, Rha SY, Seong JS, Jeung HC. Intermediate dose 5-fluorouracil-induced encephalopathy. Jpn J Clin Oncol. 2006, 36:55-59. 10.1093\/jjco\/hyi214","journal-title":"Jpn J Clin Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30321","article-title":"Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity","volume":"123","author":"Ma WW","year":"2017","unstructured":"Ma WW, Saif MW, El-Rayes BF, et al.. Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity. Cancer. 2017, 123:345-356. 10.1002\/cncr.30321","journal-title":"Cancer"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.87a.19126","article-title":"5-Fluorouracil-induced encephalopathy","volume":"87","author":"Yano Y","year":"2020","unstructured":"Yano Y, Kuriyama A. 5-Fluorouracil-induced encephalopathy. Cleve Clin J Med. 2020, 87:532-3. 10.3949\/ccjm.87a.19126","journal-title":"Cleve Clin J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A2781","article-title":"Atypical diffusion-restricted lesion in 5-Fluorouracil encephalopathy","volume":"33","author":"Lee WW","year":"2012","unstructured":"Lee WW, Kim JS, Son KR, Kwon HM. Atypical diffusion-restricted lesion in 5-Fluorouracil encephalopathy. AJNR Am J Neuroradiol. 2012, 33:E102-3. 10.3174\/ajnr.A2781","journal-title":"AJNR Am J Neuroradiol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14857","article-title":"Leukoencephalopathy with transient splenial lesions related to 5-fluorouracil or capecitabine","volume":"28","author":"Perrain V","year":"2021","unstructured":"Perrain V, Bihan K, Bompaire F, et al.. Leukoencephalopathy with transient splenial lesions related to 5-fluorouracil or capecitabine. Eur J Neurol. 2021, 28:2396-402. 10.1111\/ene.14857","journal-title":"Eur J Neurol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.1.167","article-title":"Phase I and pharmacologic study of PN401 and fluorouracil in patients with advanced solid malignancies","volume":"18","author":"Hidalgo M","year":"2000","unstructured":"Hidalgo M, Villalona-Calero MA, Eckhardt SG, et al.. Phase I and pharmacologic study of PN401 and fluorouracil in patients with advanced solid malignancies. J Clin Oncol. 2000, 18:167-77. 10.1200\/JCO.2000.18.1.167","journal-title":"J Clin Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/208601-5-fluorouracil-neurotoxicity-in-a-patient-with-normal-dihydropyrimidine-dehydrogenase-activity","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:12:29Z","timestamp":1707509549000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/208601-5-fluorouracil-neurotoxicity-in-a-patient-with-normal-dihydropyrimidine-dehydrogenase-activity"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,4]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.49898","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12,4]]}}}